Profectus BioSciences Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 15

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $11.3M

Profectus BioSciences General Information

Description

Developer of preventive, therapeutic, and oncolytic vaccines designed to treat and prevent viral diseases. The company's vaccines are used for infectious diseases and cancer immunotherapy, enabling people to get prevention from diseases like HCV, HPV, HSV, HIV, and malaria.

Contact Information

Formerly Known As
Maryland Biotherapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 6411 Beckley Street
  • Suite 201
  • Baltimore, MD 21224
  • United States
+1 (443)
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Acquirer
Aurobindo Pharma USA
Vertical(s)
Corporate Office
  • 6411 Beckley Street
  • Suite 201
  • Baltimore, MD 21224
  • United States
+1 (443)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Profectus BioSciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
23. Merger/Acquisition 11-Feb-2020 $11.3M Completed Generating Revenue
22. Grant 14-Jan-2019 Completed Generating Revenue
21. Grant 24-Aug-2018 Completed Generating Revenue
20. Grant 06-Jun-2017 Completed Generating Revenue
19. Later Stage VC 12-Dec-2016 Completed Generating Revenue
18. Grant 09-Dec-2015 Completed Generating Revenue
17. Grant 22-Oct-2014 Completed Generating Revenue
16. Later Stage VC (Series C) 04-Aug-2014 Completed Generating Revenue
15. Grant 01-Mar-2014 $5.4M $30.7M Completed Generating Revenue
14. Grant 09-May-2012 $5.6M $30.7M Completed Generating Revenue
To view Profectus BioSciences’s complete valuation and funding history, request access »

Profectus BioSciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 12,500,000 $0.000100 $0.1 $1.2 $1.2 1x $1.2 21.08%
To view Profectus BioSciences’s complete cap table history, request access »

Profectus BioSciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of preventive, therapeutic, and oncolytic vaccines designed to treat and prevent viral diseases. The company's
Discovery Tools (Healthcare)
Baltimore, MD
15 As of 2022

Athens, GA
 

Paris, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Profectus BioSciences Competitors (19)

One of Profectus BioSciences’s 19 competitors is Cyanvac, a Venture Capital-Backed company based in Athens, GA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cyanvac Venture Capital-Backed Athens, GA
Theravectys Venture Capital-Backed Paris, France
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Brainstorm Cell Therapeutics Corporation New York, NY
Sanofi Pasteur Corporation Paris, France
You’re viewing 5 of 19 competitors. Get the full list »

Profectus BioSciences Patents

Profectus BioSciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2015225553-A1 Recombinant isfahan viral vectors Active 01-Mar-2014
AU-2015225553-B2 Recombinant isfahan viral vectors Inactive 01-Mar-2014
CA-2941261-A1 Recombinant isfahan viral vectors Pending 01-Mar-2014
EP-3113795-A2 Recombinant isfahan viral vectors Active 01-Mar-2014
EP-3113795-A4 Recombinant isfahan viral vectors Active 01-Mar-2014 C12N7/00
To view Profectus BioSciences’s complete patent history, request access »

Profectus BioSciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Profectus BioSciences Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aberdeen Proving Ground Government
Cross Atlantic Capital Partners Venture Capital Minority
Department of the Army Government
Division of AIDS Government
Maryland Industrial Partnerships University Minority
You’re viewing 5 of 9 investors. Get the full list »

Profectus BioSciences Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
rel-MD Baltimore, MD 2011

Profectus BioSciences FAQs

  • When was Profectus BioSciences founded?

    Profectus BioSciences was founded in 2002.

  • Where is Profectus BioSciences headquartered?

    Profectus BioSciences is headquartered in Baltimore, MD.

  • What is the size of Profectus BioSciences?

    Profectus BioSciences has 15 total employees.

  • What industry is Profectus BioSciences in?

    Profectus BioSciences’s primary industry is Discovery Tools (Healthcare).

  • Is Profectus BioSciences a private or public company?

    Profectus BioSciences is a Private company.

  • What is the current valuation of Profectus BioSciences?

    The current valuation of Profectus BioSciences is .

  • What is Profectus BioSciences’s current revenue?

    The current revenue for Profectus BioSciences is .

  • How much funding has Profectus BioSciences raised over time?

    Profectus BioSciences has raised $38.5M.

  • Who are Profectus BioSciences’s investors?

    Aberdeen Proving Ground, Cross Atlantic Capital Partners, Department of the Army, Division of AIDS, and Maryland Industrial Partnerships are 5 of 9 investors who have invested in Profectus BioSciences.

  • Who are Profectus BioSciences’s competitors?

    Cyanvac, Theravectys, Inovio Pharmaceuticals, Brainstorm Cell Therapeutics, and Sanofi Pasteur are some of the 19 competitors of Profectus BioSciences.

  • When was Profectus BioSciences acquired?

    Profectus BioSciences was acquired on 11-Feb-2020.

  • Who acquired Profectus BioSciences?

    Profectus BioSciences was acquired by Aurobindo Pharma USA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process